Zenyaku Kogyo Co., Ltd. and Chugai Pharmaceutical Co., Ltd. have announced obtaining approval from Japan's Ministry of Health, Labour and Welfare to commercially distribute Rituxan®.

Ubiquitination is a process that involves adding a protein called ubiquitin to a substrate protein.

Mineralys Therapeutics Reports Initial Participant Receives Dose in Start-HTN, Their Second Major Study of Lorundrostat Aimed at Hypertension Management.

H2 receptor antagonists are drugs that inhibit histamine action in the stomach, reducing acid production.

Jazz Pharmaceuticals plc announced early results from its Phase 2 trial evaluating the efficacy and safety of JZP150, a selective FAAH enzyme inhibitor, in adults with PTSD.

Drug delivery can be significantly affected by the pH of the environment in which it occurs.

The FDA has sanctioned an update to the packaging of Kite Pharma's Yescarta® treatment, now incorporating information on patient survival rates.

CGRP antagonists are drugs that block the CGRP receptor, used in preventing migraines.

WAINUA™ (eplontersen) Receives Groundbreaking US Sanction as a Treatment for Polyneuropathy in Adult Hereditary Transthyretin Amyloidosis Cases.

The solubility of a drug can significantly impact its bioavailability, absorption rate, and ultimately, its effectiveness as a therapeutic agent.

Sanofi has terminated its study of tusamitamab ravtansine due to a Phase 3 trial in second-line NSCLC failing to achieve its main goal.

D2 receptor agonists are drugs that activate the D2 subtype of dopamine receptors, used in treating conditions like Parkinson’s disease and hyperprolactinemia.